KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Change in Accured Expenses (2018 - 2025)

Historic Change in Accured Expenses for Vir Biotechnology (VIR) over the last 8 years, with Q3 2025 value amounting to -$14.2 million.

  • Vir Biotechnology's Change in Accured Expenses fell 17346.38% to -$14.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$14.4 million, marking a year-over-year increase of 7392.49%. This contributed to the annual value of -$10.3 million for FY2024, which is 9711.44% up from last year.
  • Per Vir Biotechnology's latest filing, its Change in Accured Expenses stood at -$14.2 million for Q3 2025, which was down 17346.38% from -$24.2 million recorded in Q2 2025.
  • Over the past 5 years, Vir Biotechnology's Change in Accured Expenses peaked at $433.6 million during Q1 2022, and registered a low of -$288.2 million during Q2 2022.
  • In the last 5 years, Vir Biotechnology's Change in Accured Expenses had a median value of -$14.2 million in 2025 and averaged -$18.1 million.
  • Over the last 5 years, Vir Biotechnology's Change in Accured Expenses had its largest YoY gain of 240284.17% in 2022, and its largest YoY loss of 822875.72% in 2022.
  • Quarter analysis of 5 years shows Vir Biotechnology's Change in Accured Expenses stood at $72.0 million in 2021, then plummeted by 212.04% to -$80.7 million in 2022, then surged by 50.93% to -$39.6 million in 2023, then surged by 113.25% to $5.2 million in 2024, then tumbled by 369.98% to -$14.2 million in 2025.
  • Its Change in Accured Expenses stands at -$14.2 million for Q3 2025, versus -$24.2 million for Q2 2025 and $18.7 million for Q1 2025.